Adrenocortical Carcinoma in Children

0
16


Adrenocortical Carcinoma in Children

Related Links:

AbstractAdvanced adrenocortical carcinoma (ACC) is an aggressive disease with poor prognosis, and the current therapeutic options, such as mitotane or platinum‐based chemotherapy regimens, often offer limited efficacy. Here, we present the first report, to the author’s knowledge, of metastatic ACC with positive octreoscan scintigraphy that was successfully treated with octreotide long‐acting release (LAR). A patient with metastatic ACC who showed poor tolerance to mitotane received octreotide LAR because of positive octreoscan scintigraphy. She obtained major partial response to the somatostatin analog. Interestingly, …

Source: The OncologistCategory: Cancer & Oncology Authors: Tags: Endocrinology Brief Communication Source Type: research

CONCLUSIONS: Zebrafish embryo xenografted with ACC tumor cells could be a useful, fast and reproducible experimental model to preclinically test the activity of new drugs potentially active in human ACC.
PMID: 31397841 [PubMed – as supplied by publisher]

Source: EndocrinologyCategory: Endocrinology Authors: Tags: Endocrinology Source Type: research

ConclusionsIGF2 is an excellent marker to differentiate ACC from ACAn. In addition, IGF2 was demonstrated to influence adrenocortical cancer cell proliferation, metabolism, and viability, but not the cell invasion. These data support that different IGF2 concentrations in ACC can be responsible for different biological behaviors of ACC.

Source: EndocrineCategory: Endocrinology Source Type: research

British Journal of Cancer, Published online: 31 July 2019; doi:10.1038/s41416-019-0538-yEZH2 cooperates with E2F1 to stimulate expression of genes involved in adrenocortical carcinoma aggressiveness

Source: British Journal of CancerCategory: Cancer & Oncology Authors: Source Type: research

ConclusionReduced expression of FPN1 and CP was identified as a potential signature for poor prognosis of ACC in this study. Mechanisms underlying the prognostic value of FPN1 or CP in ACC deserve further experimental investigation.Graphical abstract

AbstractPurposeTo assess the diagnostic performance of the H-score of 11 β-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) in the histopathological diagnosis of adrenocortical tumors (ACT).MethodsWe retrospectively evaluated 199 cases of ACT, of which 85 were diagnosed as aldosterone-producing adenoma (APA), 66 as cortisol-producing adenoma (CPA), 9 as aldosterone –cortisol co-secreting adenoma, 30 as nonhyperfunctioning adenoma, and 9 as adrenocortical carcinoma (ACC). Immunohistochemical staining was performed using anti-CYP11B1 and anti-CYP11B2 monoclonal antibodies. The staining was quantified by th…

Source: EndocrineCategory: Endocrinology Source Type: research

Publication date: Available online 12 July 2019Source: Best Practice &Research Clinical Endocrinology &MetabolismAuthor(s): Hadiza S. Kazaure, Julie A. SosaThe relationship between operative volume and perioperative outcomes after several oncologic operations is well documented. Recent studies on adrenalectomy reveal a robust association between higher surgeon volume and improved patient outcomes. Statistical analyses have demonstrated that outcomes are improved when surgeons perform at least six adrenalectomies annually; based on this threshold definition of a ‘high-volume’ surgeon, more than 80% of ad…

Conclusions: Our findings emphasize HSP90 as a marker with prognostic impact and promising target with N-terminal HSP90 inhibitors as drugs with potential therapeutic efficacy towards ACC.

In conclusion, DEGs and hub genes diagnosed in this study may deepen our understanding of molecular mechanisms underlying the progression of ACC, and pr ovide important targets for diagnosis and treatment of ACC.

Source: Medical OncologyCategory: Cancer & Oncology Source Type: research

Publication date: Available online 12 July 2019Source: Best Practice &Research Clinical Endocrinology &MetabolismAuthor(s): Hadiza S. Kazaure, Julie A. SosaAbstractThe relationship between operative volume and perioperative outcomes after several oncologic operations is well documented. Recent studies on adrenalectomy reveal a robust association between higher surgeon volume and improved patient outcomes. Statistical analyses have demonstrated that outcomes are improved when surgeons perform at least six adrenalectomies annually; based on this threshold definition of a ‘high-volume’ surgeon, more than 8…



Source link